Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

To gain a better understanding of the role of somatic mutations in olaparib response, next-generation sequencing (NGS) of BRCA1 and BRCA2 was performed as part of a planned retrospective analysis of tumors from a randomized, double-blind, Phase II trial (Study 19; D0810C00019; NCT00753545) in 265 pa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Dougherty, Brian A., Lai, Zhongwu, Hodgson, Darren R., Orr, Maria C.M., Hawryluk, Matthew, Sun, James, Yelensky, Roman, Spencer, Stuart K., Robertson, Jane D., Ho, Tony W., Fielding, Anitra, Ledermann, Jonathan A., Barrett, J. Carl
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546431/
https://ncbi.nlm.nih.gov/pubmed/28525389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17613
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares